CD8A and neoplasm: Targeting VEGFR2 with ramucirumab increased PD-L1 expression and CD8+ T cell infiltration in the tumor microenvironment of patients with advanced gastric cancer and reduced the frequency of immunosuppressive effector regulatory T cells in tumor-infiltrating lymphocytes [25].